(+)-4-[(αR)-α-((2S,5R)-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide | 687996-30-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (+)-4-[(αR)-α-((2S,5R)-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide
• 英文别名: 4-((alpha-R)-alpha-((2S,5R)-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamide；4-[(R)-[(2S,5R)-2,5-dimethylpiperazin-1-yl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide
• CAS: 687996-30-1
• 化学式: C₂₅H₃₅N₃O₂
• 分子量: 409.572
• InChiKey: ORJHTPASYZWOQJ-YDIMBITNSA-N

物化性质

• 沸点：
  546.5±50.0 °C(Predicted)
• 密度：
  1.055±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  44.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-氟溴苄 、 (+)-4-[(αR)-α-((2S,5R)-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide 在 三乙胺 、 sodium iodide 作用下， 以 乙腈 为溶剂， 生成 4-((alpha-R)-alpha-((2S,5R)-2,5-dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamide
  参考文献：
  名称：

  WO2007/27987

  摘要：

  公开号：
• 作为产物：
  描述：

  (+)-4-[(ΑR)-Α-((2S,5R)-4-烯丙基-2,5-二甲基-1-哌嗪基)-3-甲氧基苄基]-N,N-二乙基苯酰胺 在 1,4-双(二苯基膦)丁烷 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 硫代水杨酸 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 (+)-4-[(αR)-α-((2S,5R)-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide
  参考文献：
  名称：

  WO2007/27987

  摘要：

  公开号：

文献信息

• METHOD OF TREATING PARKINSON'S DISEASE WITH DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA RECEPTOR AGONIST ACTIVITY
  申请人：Chang Kwen-Jen

  公开号：US20070066625A1

  公开（公告）日：2007-03-22

  Compositions and methods for treatment of Parkinson's disease to reduce the negative side effects of the disease by administering a therapeutically effective diarylmethylpiperazine compound which exhibits delta opioid receptor agonist activity, and optionally, mu receptor antagonist activity.

  本发明涉及一种治疗帕金森病的组合物和方法，通过给予具有δ-阿片受体激动剂活性的治疗有效的二苯甲基哌嗪化合物来减轻疾病的负面副作用，可选地，还包括μ-阿片受体拮抗剂活性。
• METHOD OF TREATING PARKINSON'S DISEASE WITH A DIARYLMETHYLPIPERAZINE COMPOUNDS EXHIBITING DELTA OPIOID RECEPTOR AGONIST ACTIVITY
  申请人：CHANG KWEN-JEN

  公开号：US20140315922A1

  公开（公告）日：2014-10-23

  Compositions and methods for treatment of Parkinson's disease to reduce the negative side effects of the disease by administering a therapeutically effective diarylmethylpiperazine compound which exhibits delta opioid receptor agonist activity, and optionally, mu receptor antagonist activity.

  本发明涉及一种治疗帕金森病的组合物和方法，通过给予一种具有δ阿片受体激动剂活性的治疗有效的二芳基甲基哌嗪化合物，来减少疾病的负面副作用，可选地，该化合物还具有μ阿片受体拮抗剂活性。
• Method of treating Parkinson's Disease with diarylmethylpiperazine compounds exhibiting delta receptor agonist activity
  申请人：Chang Kwen-Jen

  公开号：US08642599B2

  公开（公告）日：2014-02-04

  Compositions and methods for treatment of Parkinson's disease to reduce the negative side effects of the disease by administering a therapeutically effective diarylmethylpiperazine compound which exhibits delta opioid receptor agonist activity, and optionally, mu receptor antagonist activity.

  治疗帕金森病的组合物和方法，通过给予具有δ阿片受体激动剂活性的治疗有效的二芳基甲基哌嗪化合物，可选地，还包括μ阿片受体拮抗剂活性，以减少疾病的负面副作用。
• Method of treating Parkinson's Disease with a diarylmethylpiperazine compounds exhibiting delta opioid receptor agonist activity
  申请人：VERSI GROUP, LLC

  公开号：US10071093B2

  公开（公告）日：2018-09-11

  Compositions and methods for treatment of Parkinson's disease to reduce the negative side effects of the disease by administering a therapeutically effective diarylmethylpiperazine compound which exhibits delta opioid receptor agonist activity, and optionally, mu receptor antagonist activity.

  用于治疗帕金森病的组合物和方法，通过施用具有治疗效果的二芳基甲基哌嗪化合物来减少帕金森病的负面副作用，该化合物具有δ阿片受体激动剂活性，并可选择具有μ受体拮抗剂活性。
• Probes for Narcotic Receptor-Mediated Phenomena. 27. Synthesis and Pharmacological Evaluation of Selective δ-Opioid Receptor Agonists from 4-[(α<i>R</i>)-α-(2<i>S</i>,5<i>R</i>)-4-Substituted-2,5-dimethyl-1-piperazinyl-3-methoxybenzyl]- <i>N</i>,<i>N</i>-diethylbenzamides and Their Enantiomers
  作者：M. Scott Furness、Xiaoyan Zhang、Andrew Coop、Arthur E. Jacobson、Richard B. Rothman、Christina M. Dersch、Heng Xu、Frank Porreca、Kenner C. Rice

  DOI：10.1021/jm0001222

  日期：2000.8.1

  Potent, selective, and efficacious delta-opioid receptor agonists such as (+)-4-[(alpha R)-alpha-(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl-3-methoxybenzyl]-N,N-diethylbenzamide [SNC80, (+)-2] have been found to be useful tools for exploring the structural requirements which are necessary for ligands which interact with the delta-receptor. To determine the necessity for the 4-allyl moiety in (+)-2, this substituent was replaced with a variety of 4-alkyl, 4-arylalkyl, and 4-alkenyl substituents. The corresponding enantiomers of these compounds were also synthesized. The binding affinities for the mu-, delta-, and kappa-opioid receptors and efficacies in the functional GTP gamma S binding assay were determined for the (+)-2 related compounds and their enantiomers. The 4-crotyl analogue was found to have similar delta-receptor affinity and efficacy as (+)-2, but the 4-cyclopropylmethyl analogue, in the functional assay, appeared to be a partial agonist with little antagonist activity.